Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.28

+5.3%

Nov 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (13151)	9/27/2004 10:14:28 PM
From: Miljenko Zuanic	Read Replies (2) of 52153

What's quite intriguing/interesting for me is the mechanism of action.. And that is….???? 1067 is monosuccinic acid ester of the Probucol, old and known anti-oxidant. This derivatization make Prubucol water soluble. Now they are talking about anti-inflammatory property, down-regulation of the VCAM-1. Well, in post-PCI restenosis this anti-VCAM-1 property are not yet confirmed. Today result only confirm that 12 months post-stent PCI plague volume are back to pre-PCI level, with small difference using 1067. Seems that 1067 dosing before PCI helped bit. Now, what about lumina volume and area? Without control arm, no drug at all (only standard of care), we do not know what will be true 1067 athrerosclerosis benefit. Second, will this translate into medical benefit that ARISE study is looking at? Well, only full data from CART-2 can help to speculate about ARISE outcome. But, history experience from this type of the press release (with end-point change) I will speculate negative outcome as most likely scenario. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next